Uso do omalizumabe na urticária crônica espontânea: o que fazer após 6 meses?
Use of omalizumab in chronic spontaneous urticaria: what to do after 6 months?
Paula Natassya Argolo; Bruna Gehlen; Mariana Mousinho-Fernandes; Jorge Kalil; Antônio Abilio Motta; Rosana Câmara Agondi
Resumo
A urticária crônica espontânea (UCE) é uma condição rara, benigna e com sintomas que afetam adversamente a qualidade de vida, tanto dos pacientes quanto de seus familiares, visto que ainda não existe tratamento resolutivo. O manejo farmacológico de primeira linha consiste no uso de anti-histamínicos em doses licenciadas ou até quadruplicadas, e na ausência de resposta ao anti-histamínico, os consensos mundiais recomendam, na sequência, a adição de omalizumabe. Ambos são amplamente utilizados e considerados seguros e eficazes. No entanto, ainda há alguns questionamentos acerca da anti-IgE: quando e como suspender a medicação, por quanto tempo usar ou quando retornar o uso da mesma, caso haja recidiva. Logo, alguns artigos foram revisados visando melhor elucidação dessas dúvidas.
Palavras-chave
Abstract
Chronic spontaneous urticaria (CSU) is a rare, benign condition with symptoms that adversely affect the patients' and their families' quality of life, as there is still no curative treatment. First-line pharmacological management consists of the use of antihistamines in licensed or even quadruplicate doses and, if there is no response to the antihistamine, worldwide consensus recommends subsequent addition of omalizumab. Both are widely used and considered safe and effective. However, there are still some questions about anti-IgE, including when and how to stop the medication, how long it should be used, and when to resume using it in the case of a relapse. Therefore, some articles were reviewed to facilitate the elucidation of these questions.
Keywords
Referências
1. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, BallmerWeber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393-414.
2. Türk M, Carneiro-Leão L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J Allergy Clin Immunol Pract. 2020;8:113-24.
3. Maurer M, Church MK, Marsland AM, Sussman G, Siebenhaar F, Vestergaard FC, et al. Questions and answers in chronic urticaria: where do we stand and where do we go? European Academy of Dermatology and Venereology. 2016;30(Suppl. 5):7‑15.
4. Maurer M, Ortonne JP, Zuberbier T. Chronic urticaria: a patient survey on quality-of-life, treatment usage and doctor-patient relation. Allergy. 2009;64:581-8.
5. Giménez Arnau AM, Valero Santiago A, Bartra Tomás J, Jáuregui Presa I, Labrador-Horrillo M, Miquel FJ, et al. Therapeutic strategy according to differences in response to omalizumab in patients with chronic spontaneous urticaria. J Investig Allergol Clin Immunol. 2019;29(5):338‑48.
6. Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137:474-81.
7. Sánchez J, Alvarez L, Cardona R. Cyclosporine and omalizumab together: a new option for chronic refractory urticaria. J Allergy Clin Immunol Pract. 2020; Epub ahead of print.
8. Deza G, Ricketti PA, Giménez-Arnau AM, Casale TB. Emerging biomarkers and therapeutic pipelines for chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2018;6:1108-17.
9. Rabelo-Filardi R, Daltro-Oliveira R, Campo RA. Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review. Int Arch Allergy Immunol. 2013;161:197‑204.
10. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, Gozález-Aveledo L, Maurer M. Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017;31:964-71.
11. Kolkhir P, Altrichter S, Hawro T, Maurer M. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy. 2018;73:940-8.
12. Schoepke N, Asero R, Ellrich A, Ferrer M, Giménez-Arnau A, Grattan CEH, et al. Biomarkers and clinical characteristics of autoimune chronic spontaneous urticaria: results of the PURIST study. Allergy. 2019;74:2427-36.
13. Hemmings O, Kwok M, McKendry R, Santos AF. Basophil activation test: old and new applications in allergy. Curr Allergy Asthma Rep. 2018;18:77.
14. Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov PS, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139:1059‑61.
15. Incorvaia C, Mauro M, Makri E, Leo G, Ridolo E. Two decades with omalizumabe: what we still have to learn. Biologics: Targets and Therapy. 2018;12:135-42.
16. Türk M, Yilmaz I, Bahçecioglu SN. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients. Allergology International. 2018;67:85-9.
17. Silva PM, Costa AC, Mendes A, Barbosa MP. Long-term efficacy of omalizumab in seven patientswith treatment-resistant chronic spontaneous urticaria. Allergol Immunopathol (Madr). 2015;43(2):168-73.
18. Francés L, Leiva-Salinas M, Silvestre JF. Omalizumabe in the treatment of chronic urticaria. Actas Dermosifiliogr. 2014;105:45‑52.
19. Kaplan AP. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72:519‑33.
20. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567‑73.
21. Ferrer M, Boccon-Gibod I, Gonçalo M, Ínalöz HS, Knulst A, Lapeere H, et al. Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria. Eur J Dermatol. 2017;27:455‑63.
22. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an offective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73:57‑62.
23. Curto-Barredo L, Spertino J, Figueras-Nart I, Exposito-Serrano V, Guilabert A, Mele-Ninot G, et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. Br J Dermatol. 2018;179:210-2.
24. Türk M, Maurer M, Yilmaz I. How to discontinue omalizumab in chronic spontaneous urticaria? Allergy. 2019;74:821-4.
25. Metz M, Ohanyan T, Church MK, Maurer M. Reatreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatoly. 2014;150:288-90.
26. Marcelino J, Costa C, Aguiar P, Pereira-Barbosa M. Identificação de diferentes padrões de resposta ao omalizumab em doentes com urticária crônica espontânea. Rev Port Imunoalergologia. 2018;26:109-19.
27. Galvão VR, Castells MC. Hypersensitivity to biological agentsupdated diagnosis, management and treatment. J Allergy Clin Immunol Pract. 2015;3:175-85.
28. Ertas R, Özyurt K, Yildiz S, Ulas Y, Turasan A, Avci A. Adverse reaction to omalizumab in patients with chronic urticaria: flare up or ineffectiveness? Iran J Allergy Asthma Immunol. 2016;15:82-6.
Submetido em:
15/05/2020
Aceito em:
23/06/2020
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email